MedTrace Logo

A Study of YM178 in Patients With Symptomatic Overactive Bladder

NCT00527033 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 842

Last updated 2024-10-31

No results posted yet for this study

Summary

Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

YM178

Oral

DRUG

Placebo

Oral

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-11
Primary Completion
2008-04-03
Completion
2008-04-03

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00527033 on ClinicalTrials.gov